The global Radioligand Therapy (RLT) market is poised to reach US$13 billion by 2030, expanding at a ~5% CAGR over the ...

Julien Torgue, Chief Scientific Officer of Orano Med, stated: “The expansion of our R&D center enhances our ability to develop lead-212-based radioligand therapies by giving our teams the resources ...

With an investment of over $5 million, Orano Med has expanded its R&D Center by approximately 11,000 ft². The expansion includes around 5,000 ft² of new laboratory space, enabling the advancement of a ...

PARIS, June 26, 2025--Orano Med, a pioneer in radioligand therapies in oncology, inaugurated the expansion of its R&D Center located in Plano, Texas (USA).

Orano Med, a subsidiary of the Orano Group and a pioneer in radioligand therapies in oncology, today inaugurated the expansion of its main Research and Development Center located in Plano, Texas ...

Molecular Partners and Orano Med are developing targeted alpha radio-therapeutics against up to ten targets, including the tumor-associated protein Delta-like ligand 3 (DLL3) and mesothelin (MSLN).

MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with Orano Med Promising tumor ...

Molecular Partners and Orano Med are developing targeted alpha radio-therapeutics against up to ten targets, including the tumor-associated protein Delta-like ligand 3 (DLL3) and mesothelin (MSLN).